Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adjuvanted and un-adjuvanted influenza vaccines · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Adjuvanted and un-adjuvanted influenza vaccines | BIOLOGICAL | 16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator. |
Inclusion Criteria: * Children of 6 month to \<36 month of age in good health as determined by medical history, physical assessment and clinical judgement of the investigator. Exclusion Criteria: * History of serious disease. History of serious reaction following administration of vaccine or hype...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
It is an investigational influenza vaccine developed by Novartis AG (ticker NVS) that combines adjuvanted and non-adjuvanted formulations. It was studied in healthy children aged 6 to under 36 months for the prevention of influenza. The program reached Phase 1 clinical development.
It is being studied for the prevention of influenza in young children. The single Phase 1 trial enrolled healthy children 6 to under 36 months of age. The vaccine combines adjuvanted and non-adjuvanted formulations to evaluate different dose combinations for influenza protection.
Novartis AG, which trades under the ticker NVS, is the developer of the adjuvanted and un-adjuvanted influenza vaccine. The company sponsored the Phase 1 dose-ranging study conducted in Belgium. Novartis is the sole developer named for this influenza vaccine candidate.
The adjuvanted and un-adjuvanted influenza vaccine is in Phase 1 development. It is investigational and has not been approved. The only trial, NCT00848887, is a completed Phase 1 dose-ranging study. No active trials are currently listed for this candidate.
One clinical trial has evaluated the adjuvanted and un-adjuvanted influenza vaccine: NCT00848887, a Phase 1 dose-ranging study comparing different combinations of adjuvanted and non-adjuvanted influenza vaccines in healthy children 6 to under 36 months of age. The trial enrolled 410 participants in Belgium and is completed.
NCT00848887 was a Phase 1 dose-ranging study comparing different combinations of adjuvanted and non-adjuvanted influenza vaccines. It enrolled 410 healthy children aged 6 to under 36 months in Belgium. The study was randomized and uncontrolled, and it has been completed.